29.54

2.07% 0.60

Celldex Therapeutics Inc (CLDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Celldex Therapeutics Inc stock is traded at $29.54, with a volume of 875.40K. It is up +2.07% in the last 24 hours and up +21.71% over the past month. Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Previous Close:

$28.94

Open:

$29.06

24h Volume:

875.40K

Relative Volume:

1.12

Market Cap:

$1.96B

Revenue:

$5.79M

Net Income/Loss:

$-199.61M

P/E Ratio:

-9.814

EPS:

-3.01

Net Cash Flow:

$-188.48M

1W Performance:

-4.15%

1M Performance:

+21.71%

6M Performance:

+29.68%

1Y Performance:

+47.70%

1-Day Range:

$28.95

$30.14

1-Week Range:

$28.72

$31.31

52-Week Range:

$14.40

$31.31

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name

Celldex Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

908-200-7500

Address

53 FRONTAGE ROAD, HAMPTON

Employee

186

Twitter

@search?q=celldex

Next Earnings Date

2024-11-04

Latest SEC Filings

CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDX Celldex Therapeutics Inc	29.54	1.92B	5.79M	-199.61M	-188.48M	-3.01
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Mizuho	Outperform
Oct-13-25	Initiated	Barclays	Underweight
Apr-28-25	Initiated	Canaccord Genuity	Buy
Mar-20-25	Initiated	Morgan Stanley	Overweight
Feb-13-25	Initiated	UBS	Buy
Oct-07-24	Initiated	Citigroup	Buy
Sep-30-24	Initiated	Goldman	Neutral
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Aug-22-23	Initiated	Wells Fargo	Underweight
Sep-17-21	Initiated	Jefferies	Buy
Sep-10-21	Initiated	SVB Leerink	Outperform
Jul-22-21	Initiated	Guggenheim	Buy
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight
Aug-01-17	Resumed	H.C. Wainwright	Buy
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy
Aug-11-15	Reiterated	Brean Capital	Buy
Aug-11-15	Reiterated	Oppenheimer	Outperform
Aug-11-15	Reiterated	ROTH Capital	Buy
Jun-02-15	Reiterated	WBB Securities	Strong Buy
Nov-17-14	Reiterated	ROTH Capital	Buy
Mar-04-14	Reiterated	Oppenheimer	Outperform
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy
Feb-26-13	Reiterated	Oppenheimer	Outperform
Jan-10-13	Reiterated	Cantor Fitzgerald	Buy
Oct-02-12	Reiterated	Oppenheimer	Outperform
Sep-14-12	Reiterated	Cantor Fitzgerald	Buy

View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

Mar 04, 2026

Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Mar 04, 2026

Mar 03, 2026